Nautilus Biotechnology, Inc. (NAUT) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on the Nautilus Voyager™ platform, a proteomics technology utilizing Iterative Mapping to quantify single, intact protein molecules. The company is currently in the early stages of commercialization, having launched an "Early Access Program" in January 2026 for targeted proteoform analysis (specifically Tau and AKT1 assays). The company operates as a single reportable segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $190 | $190 | $0 |
| Net Loss | $(14,469) | $(29,166) | $(31,646) |
| Net Loss Per Share (Basic & Diluted) | $(0.11) | $(0.23) | $(0.25) |
| Operating Expenses | $15,938 | $32,062 | $35,941 |
| Research & Development | $9,613 | $19,320 | $21,930 |
| Selling, General & Administrative | $6,325 | $12,742 | $14,011 |
| Cash, Cash Equivalents & Investments | $129,195 (as of June 30, 2026) | ||
| Accumulated Deficit | $(361,186) (as of June 30, 2026) |
Note: Revenue consists of $180,000 in grant revenue from The Michael J. Fox Foundation and $10,000 in service revenue from the Early Access Program.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded its first material revenue in Q2 2026 ($190,000 total for the quarter and six months), driven by the commencement of grant activities and the Early Access Program. This is a significant change from the prior year periods where revenue was $0.
- Expense Reduction: Total operating expenses decreased by 11% year-over-year for the six-month period (from $35.9M to $32.1M).
- R&D Expenses: Decreased by 12% ($2.6M), primarily due to a $1.1M reduction in salaries/benefits (following a Q1 2025 workforce reduction) and a $0.5M decrease in stock-based compensation.
- SG&A Expenses: Decreased by 9% ($1.3M), driven by lower stock-based compensation and salary costs, partially offset by increased professional fees.
- Interest Income: Decreased by 37% year-over-year (from $4.3M to $2.7M for the six months) due to lower investment balances and decreased yield rates.
- Liquidity: Cash, cash equivalents, and short-term investments totaled $84.0 million as of June 30, 2026, down from $105.9 million in total current assets at year-end 2025, reflecting operating cash burn.
Guidance, Outlook, and Risks
- Commercialization Timeline: The company expects to initiate its commercial launch in early 2027 with pre-orders, and instrument shipments to begin in mid-2027. Initial offerings will include the Voyager instrument and assays for Tau, AKT1, and an additional oncology proteoform.
- Strategic Shift: Management plans to reallocate resources from the "broadscale" assay effort to accelerate "proteoform" application development due to market demand and the need for further improvements to the broadscale assay.
- Liquidity Outlook: Management believes current cash resources ($129.2M including long-term investments) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses for the foreseeable future and will require additional capital to fund development and commercialization.
- Key Risks:
- Development Risk: The Nautilus Voyager platform remains in development; there is no assurance it will achieve commercial viability or meet performance specifications.
- Capital Requirements: The company has an accumulated deficit of $361.2 million and has never been profitable. Failure to raise additional capital could force delays or termination of operations.
- Supply Chain: Reliance on single-source suppliers for critical components and reagents poses a risk of disruption.
- Regulatory: While currently sold as "Research Use Only" (RUO), future expansion into clinical diagnostics could subject the company to FDA regulation, requiring costly approvals.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $129.2M cash/investment balance against the projected burn rate, given the expectation of continued significant losses.
- Commercial Traction: Monitor the Early Access Program for conversion to paid commercial contracts and the timeline for the 2027 instrument shipments.
- Grant Dependency: Assess the sustainability of revenue given the current reliance on the Michael J. Fox Foundation grant ($0.2M recognized in H1 2026).
- Workforce Stability: Review the impact of the Q1 2025 workforce reduction on R&D progress and the ability to execute the 2027 launch plan.
- Stock Price Compliance: Monitor compliance with Nasdaq listing requirements, specifically the $1.00 minimum bid price, as the company previously received a deficiency notice in 2025.